Roche’s Investigational Drug Tiragolumab Fails in Phase 3 Lung Cancer Study

By PacConAdmin | March 30, 2022

Roche has said its investigational monoclonal antibody, tiragolumab, combined with Tecentriq (atezolizumab) and chemotherapy did not meet the endpoints of overall survival or progression-free survival in a phase 3 study in patients with extensive-stage small-cell lung cancer (ES-SCLC).
Source: Drug Industry Daily

Posted in Drug Industry Daily